Retour

VALNEVA (EPA:VLA) Valneva Receives Marketing Authorization in Europe for Inactivated Whole-Virus COVID-19 Vaccine VLA2001

Directive transparence : information réglementée

24/06/2022 18:00

18/08/2022 18:00

Valneva Initiates Rolling Submission of FDA Biologics License Application...

18/08/2022 07:00

Valneva Provides Update on IXIARO® Supply Contract with U.S. Department...

11/08/2022 07:00

Valneva Reports H1 2022 Results and Provides Corporate Updates

08/08/2022 22:45

Pfizer and Valneva Initiate Phase 3 Study of Lyme Disease Vaccine...

26/07/2022 15:51

Original-Research: Valneva SE (von First Berlin Equity Research GmbH):...

06/07/2022 14:36

Original-Research: Valneva SE (von First Berlin Equity Research GmbH):...

24/06/2022 18:00

Valneva Receives Marketing Authorization in Europe for Inactivated...

23/06/2022 16:00

Valneva announces resumption of trading of its ordinary shares on Euronext...

23/06/2022 15:16

Valneva Receives Positive CHMP Opinion for Marketing Authorization of its...

14/04/2022 12:50

Valneva Receives Conditional Marketing Authorization from UK MHRA for its...

Voir tous les communiqués de VALNEVA